Search Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseGraft-versus-Host Disease, chronicSubgroupICD10T86.05+T86.06+T86.07+MeSHGraft vs Host DiseaseSequenceChemotherapyChemo-substanceRuxolitinibChemo-substanceRuxolitinibChemo-substanceRuxolitinibChemo-substanceRuxolitinibNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationRefractory diseaseTherapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlArthalgiaCMV Infection (asympt. + sympt.)DiarrheaEdemaEmetogenicity (MASCC/ESMO)HypertensionHypokalemiaIncrease AminotransferasesInfectionsNeutropeniaPneumoniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorZeiser RDiseaseChronische Graft-versus-Host-Erkrankung moderat oder schwer, steroidrefraktär oder steroidabhängigOriginUniversity Medical Center Freiburg, Freiburg, Germany, REACH3 TrialProtocols in Revision 1 protocol foundProtocols under revision.Ruxolitinib 10, Graft-versus-Host Disease, chronic (PID2109 V1.0)
